Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data

Curtis, Jeffrey R.; Cheng, Hong; Delzell, Elizabeth; Fram, David; Kilgore, Meredith L.; Saag, Kenneth G.; Yun, Huifeng; DuMouchel, William

doi:10.1097/mlr.0b013e318179253b

Cited by 45 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, data mining signal detection ratios were calculated to estimate signal strength associated with optic neuritis among patients receiving amiodarone. We calculated the proportional reporting ratio (PRR) 27 and the empirical Bayesian geometric mean (EBGM), 28, 29 two ratios commonly applied to voluntary adverse event reporting data.…”

Section: Methodsmentioning

confidence: 99%

Amiodarone-associated Optic Neuropathy: A Critical Review

Passman¹,

Bennett²,

Purpura³

et al. 2012

The American Journal of Medicine

View full text Add to dashboard Cite

Although amiodarone is the most commonly prescribed antiarrhythmic drug, its use is limited by serious toxicities, including optic neuropathy. Current reports of amiodarone associated optic neuropathy identified from the Food and Drug Administration's Adverse Event Reporting System (FDA-AERS) and published case reports were reviewed. A total of 296 reports were identified: 214 from AERS, 59 from published case reports, and 23 from adverse events reports for patients enrolled in clinical trials. Mean duration of amiodarone therapy before vision loss was 9 months (range 1-84 months). Insidious onset of amiodarone associated optic neuropathy (44%) was the most common presentation, and nearly one-third were asymptomatic. Optic disc edema was present in 85% of cases. Following drug cessation, 58% had improved visual acuity, 21% were unchanged, and 21% had further decreased visual acuity. Legal blindness (< 20/200) was noted in at least one eye in 20% of cases. Close ophthalmologic surveillance of patients during the tenure of amiodarone administration is warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Amiodarone-associated Optic Neuropathy: A Critical Review

Passman¹,

Bennett²,

Purpura³

et al. 2012

The American Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…Drawing on the relative reporting of infliximab adverse events to the U.S. Food and Drug Administration via the agency's adverse event reporting system (AERS) database, Hansen et al explored adverse event signals with infliximab [73]. They used the empirical Bayes geometric mean (EB05) to evaluate drug safety signals from adverse event reporting systems; the method allows for the evaluation of multiple endpoints that are not prespecified [74]. Signals were indentified for lymphoma (EB05 = 6.9), neuropathy (EB05 = 3.8), infection (EB05 = 2.9), and bowel obstruction (EB05 = 2.8) [73].…”

Section: Safety Of Long-term Tnf Antagonist Therapy In Ibdmentioning

confidence: 99%

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Oussalah¹,

Danese²,

Peyrin–Biroulet

2010

CDT

View full text Add to dashboard Cite

The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on the long-term efficacy and safety of anti-TNF therapy in IBD beyond 1 year. We searched Medline, the Cochrane Library, Embase, and Ovid Medliner for relevant studies. Infliximab, adalimumab and certolizumab are effective in maintaining clinical remission in luminal Crohn's disease. Infliximab and adalimumab are also effective in maintaining long-term fistula closure in Crohn's disease. Only infliximab has been evaluated in UC in the long term, with similar data on its effectiveness than in CD. In addition to the maintenance of clinical remission, TNF antagonists have the ability to maintain long-term mucosal healing, resulting in a reduced risk of surgery. With 2010 on the horizon, we have no good reasons to stop anti-TNF therapy in IBD patients because of its efficacy in maintaining remission and a risk-benefit ratio that remains in its favor. It is now clear that patients in deep remission, comprising clinical, biological, and endoscopic remission, are at lower risk of relapse after withdrawal of anti-TNF therapy.

show abstract

“…This approach is particularly useful when there are more than two comparison groups. Other data mining methods, such as Bayesian approaches, also have been shown to provide valid and comparable results [44].…”

Section: Methods To Characterize Patients Using Claims Datamentioning

confidence: 97%

Potential and Pitfalls of Using Large Administrative Claims Data to Study the Safety of Osteoporosis Therapies

et al. 2011

Self Cite

View full text Add to dashboard Cite

Long-term bisphosphonate use may be associated with several rare adverse events. Such associations are not optimally evaluated in conventional randomized controlled trials due to the requirements of large numbers of patients and long-term follow-up. Alternatively, administrative claims data from various sources such as Medicare have been used. Because claims data are collected for billing and reimbursement purposes, they have limitations, including uncertain diagnostic validity and lack of detailed clinical information. Using such data for pharmacoepidemiologic research requires complex methodologies that may be less familiar to many researchers and clinicians. In this review, we discuss the strengths and limitations of using claims data for osteoporosis drug safety research, summarize recent advancements in methodologies that may be used to address the limitations, and present directions for future research using claims data.

show abstract

Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data

Cited by 45 publications

References 16 publications

Amiodarone-associated Optic Neuropathy: A Critical Review

Amiodarone-associated Optic Neuropathy: A Critical Review

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Potential and Pitfalls of Using Large Administrative Claims Data to Study the Safety of Osteoporosis Therapies

Contact Info

Product

Resources

About